Company Filing History:
Years Active: 2005-2006
Title: Akihiro Morita: Innovator in Platelet Aggregation Inhibition
Introduction
Akihiro Morita is a notable inventor based in Tsu, Japan. He has made significant contributions to the field of medicine, particularly in the development of proteins that inhibit platelet aggregation. His work has the potential to impact treatments for serious cardiovascular conditions.
Latest Patents
Morita holds 2 patents related to his research. His latest patents include:
1. **Ti-4 protein derived from Triatoma infestans exhibiting activity to inhibit platelet aggregation** - This invention provides the Ti-4 protein, which is obtained from the salivary gland of Triatoma infestans. The Ti-4 protein exhibits inhibitory activity on platelet aggregation, making it a promising candidate for medicines aimed at preventing and treating myocardial infarction, pulmonary infarction, and cerebral infarction. Additionally, the Ti-4 protein serves as a lead compound in the development of novel platelet aggregation inhibitors.
2. **Ti-3 protein derived from Triatoma infestans exhibiting activity to inhibit platelet aggregation** - Similar to the Ti-4 protein, this invention provides the Ti-3 protein, also obtained from the salivary gland of Triatoma infestans. The Ti-3 protein demonstrates inhibitory activity on platelet aggregation and can be utilized in medicines for the prevention and treatment of various infarctions. It too serves as a prospective lead compound for new platelet aggregation inhibitors.
Career Highlights
Morita is affiliated with Mie University, where he conducts his research and development work. His innovative approach to studying proteins has garnered attention in the scientific community.
Collaborations
He has collaborated with notable coworkers, including Haruhiko Isawa and Masao Yuda, contributing to the advancement of his research projects.
Conclusion
Akihiro Morita's work in developing proteins that inhibit platelet aggregation represents a significant advancement in medical science. His contributions have the potential to lead to new treatments for critical health conditions.